Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for GVHD Prevention
NCT01713400Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2013
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing Ustekinumab Arm with Placebo Arm (2 arms). Primary endpoint: T Regulatory Cell (Treg)/Total Cluster of Differentiation 4 (CD4)+ Ratio at 30 days. Started Feb 2013; status: completed.
02
Drugs
ustekinumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01713400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01713400.